Combination Treatment for MRSA Nasal Carriage and MRSA-infected Wounds

submit enquiry
Life Sciences
Life Sciences

University: University of St Andrews

Sector(s): Life Sciences, Healthcare & Pharmaceuticals

About Opportunity:

Methicillin-resistant Staphylococcus aureus (MRSA) is the most common drug-resistant pathogen that can infect skin, soft tissues, major organs and the blood.  MRSA infections are often resistant to conventional antibiotics compromising effective treatment meaning new and reliable therapies are urgently required.

Patients colonised by S. aureus or MRSA are more likely to b einfected and so patients, identified as carriers prior to surgery, are treated to eradicate these pathogens.  However, resistance to mupirocin, the antibiotic of choice for reducing such carriage, is increasing and treatment failure is more often encountered.  Hence a particularly attractive opportunity exists to provide an alternative de-colonisation cream.

The new treatment is a combination of a peptide (ranalexin) with a bacteria cell wall-digesting protein (lysostaphin), which specifically targets and kills Staphylococcus aureus, including MRSA.  The combination is synergistic;these components are more active together compared to the components on their own against lysostaphin-resistant S. aureus and also vancomycin-intermediate resistant (VISA) isolates.  Furthermore, unlike conventional antibiotics the combination kills non-multyplying bacteria.

The combination is highly efficacious in vivo in an animal model, ex vivo on the surface of human skin and when dried on the surface of catheter tubing.  In animals, we demonstrated that when the combination is impregnated into dressings and applied to MRSA-infected wounds for 5 days it reduces MRSA in these lesions by >99% compared to untreated controls and wounds treated with the individual components.  The combination was more effective compared to vancomycin-treated animals.  The combination can be used topically to treat MRSA-infected wounds.

Similarly, the combination demonstrated enhanced efficacy for reducing MRSA on living human skin compared to the individual components alone.  The combination is an effective de-colonisation agent specifically capable of reducing MRSA carriage without adversely affecting the skin's normal protective microflora.

Key Benefits:

  • Combination antibacterial treatments are less likely to induce bacterial resistance


  • Topical agent to eradicate MRSA nasal carriage in pre-operative patients as an alternative to mupirocin
  • Incorparated into dressings or applied topically to treat MRSA-infected wounds
  • Anti-Staphylococcal coating for indwelling medical devices, such as catheters
  • Treatment to specifically remove Staphylococcus aureus and MRSA from skin or other surfaces

IP Status:

The University of St. Andrews has applied for International (PCT) patent protection (No. PCT/GB2007/001157) and US patent protection (no. 12/225441) The University would welcome enquiries from commercial parties interested in entering into a licensing arrangement and/or collaboration to further develop this technology.


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Lab in a Pill

    Scientists at the University of Glasgow have pioneered a new sensor technology, Lab-in-a-Pill, that could have major impact on the cost and effectiveness of bowel cancer treatment.

    Expires: Created:
  • Thermoelectric Sensor

    The Thermoelectric Sensor technology is a Nano-Calorimetric Sensor which measures very small changes in temperature. The IP provides a route to making the most sensitive calorimetric measurements (with a resolution of 0.1 mK).

    Expires: Created:
  • Parkinson's Disease Model

    The University of Glasgow is offering an exciting new model for the evaluation of new treatments for Parkinsons disease

    Expires: Created:
  • Synergistic antifungal combination

    Candida species are a major cause of catheter-related nosocomial bloodstream infections. We have identified that the combination of an echinocandin antifungal with certain antimicrobial peptides results in potent, synergistic inhibition of yeast pathogens in vitro, so offering a potential combinatio...

    Expires: Created:
  • Biocatalysis of a novel fluorinated sugar [18-F]-FDR for PET imaging

    Combining the sequential use of 2 enzymes – fluorinase and nucleoside hydrolase – we have successfully produced a new radiotracer with potential as an imaging biomarker for PET scans. The fluorinase enzyme combines fluorine with S-adenosyl-L-methionine (SAM) to generate 5'-fluro-5'-deoxy...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.